Here are the An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
An ephemeral evaluation study to find which antidiabetic drug, an ephemeral evaluation study examples, an ephemeral evaluation study to find which antidiabetic medications, an ephemeral evaluation study designs, an ephemeral evaluation study to be quiet, an ephemeral evaluation study to find which is better.
An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination
Background: The global scenario of Diabetes Mellitus is worsening every day irrespective of so many positive moves to mitigate it by WHO guided Health awareness programs and treatment protocols. Even now health professionals are engaged in managing its complications rather than treatment as such. A major portion of sufferers of this deadly disease need attention to reduce the sequelae of insulin insensitivity or insulin resistance like dysfunction in lipid, carbohydrate, and protein metabolism. To achieve the same, it is unavoidable to increase the pill count. Most of the drugs can't be boxed into fixed-dose combinations. Choosing a drug with a pleiotropic effect for a disease is the need of the hour. Both study drugs are known for their pleiotropic effects. The study drug used is metformin higher dose of 850 mg twice daily against teneligliptin (DPP4 Inhibitor) 20 mg once daily with metformin 500mg twice daily combination. This study was conducted t o find which antidiabetic can better act as hypolipidemic as well. Method: The study tenure was from May 2020 – October 2020, a total of 6 months. Overall, one hundred and sixty patients were assessed; among them hundred members were selected and ninety-one completed the study. The members were included as per the inclusion criteria. Research significance: This study aims to explore the synergistic effects of combining Teneligliptin 20 mg once daily with Metformin 500 mg twice daily on lipid profile improvement in patients with Type 2 Diabetes Mellitus (T2DM). While Metformin is a well-established first-line treatment, its efficacy at higher doses may come with increased side effects. By integrating Teneligliptin, a DPP-4 inhibitor, with Metformin at a moderate dose, we hypothesize that this combination will not only provide effective glycemic control but also offer superior lipid profile management. The findings could suggest a more effective and safer therapeutic strategy, reduc ing the need for higher Metformin doses and minimizing associated risks. Therefore, the combination of Teneligliptin with Metformin is a promising therapeutic approach for T2DM management. © 2024, Texila International Journal (TIJ). All rights reserved.
Authors : Soujania Singh G.; Brigida S.; Elizabeth A.A.; Lella T.; Vishnu Priya G.
Source : Texila International Journal (TIJ)
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.21522/TIJPH.2013.12.04.Art032 |
| ISSN | 25203134 |
| Volume | 12 |
You can download the article here
If You have any problem, contact us here